Welcome to our dedicated page for E-Buy Home news (Ticker: EBYH), a resource for investors and traders seeking the latest updates and insights on E-Buy Home stock.
E-BUY HOME INC (OTC: EBYH), doing business as Strainsforpains, Inc., features frequent news updates that describe its activities in healthcare data technology, cannabinoid-based products, and artificial intelligence. Company press releases highlight developments in its proprietary medical cannabis app, CBD product commercialization, and collaborations with research institutions and biotech partners.
News items commonly focus on Strainsforpains’ AI-driven healthcare app, which the company states is designed to help doctors, nurses, dispensaries, and patients compare cannabis strains and cannabinoid combinations with major illnesses. Updates also cover collaborations with institutions such as Mt. Sinai in New York City and Johns Hopkins in Baltimore, where the company reports working on advanced AI data integrations and professional analytics for pain management and other critical ailments.
Another key theme in EBYH news is the commercialization of CBD products. Releases describe distribution orders for CBD body creams through pharmacies, wellness centers, and CBD and health markets in the New York City and Tri-State area, as well as plans for ingestible products and the use of water-soluble, nanoliposomal encapsulation technology. The company also reports partnerships with hemp farmers in Virginia and Pennsylvania and the use of its Pennsylvania facility for production and storage.
Investors and observers following EBYH news will also see coverage of strategic agreements with Cannabis Science, Inc. and GenBio, along with event and media initiatives such as the 1-Million Strong Killing Cancers, Fight Club MMA series and related fundraising efforts. Together, these updates provide insight into how Strainsforpains presents its progress in AI healthcare tools, cannabinoid research collaborations, product launches, and awareness campaigns.
For those tracking EBYH, the news stream offers ongoing context on the company’s stated strategy in health, wellness, medical cannabis, and AI-enabled data technology.
Strainsforpains (OTC: EBYH) reported significant growth in 2024 with over $300,000 in CBD sales and projects reaching $2 million in sales by end of 2025. The company operates from a 7-acre facility in Pennsylvania, strategically located near Amazon's $650 million AI data center grid.
The company is expanding through multiple initiatives including: new CBD formulations with Australian plum extract, planned collaborations with influencers and athletes, and development of an AI-powered app for healthcare professionals. The company maintains research partnerships with institutions like Harvard, Mt. Sinai, and Johns Hopkins, and has established joint ventures with Cannabis Science Inc., GenBio, and Cannasphere Biotech for drug development and CBD product innovation.
Additional growth plans for 2025 include launching a podcast and TV show across major streaming platforms, and the CEO's upcoming book release on cannabis and pain management in February 2025.
Strainsforpains (OTC: EBYH) announces the media kit release for their Inaugural 1-Million Strong Killing Cancers Fight Club VIP Fundraiser Event in Miami, Florida. The event aims to raise $20 million for affordable cancer treatments and includes a Live Fashion Show, Live Concerts, and an MMA 'Fighting Cancer Night'. The event will also support Hurricane Relief efforts in the affected areas. The company plans to expand into quarterly live televised MMA events across the top 10 populated cities, incorporating diverse entertainment elements to drive awareness for Cannabis Science's cancer treatment initiatives. The company is also working with Mt. Sinai and John Hopkins to develop AI-powered cannabis-based treatments.
Strainsforpains (OTC: EBYH) announces collaboration with Mt. Sinai Hospital in New York City and Johns Hopkins in Baltimore to integrate advanced AI data into its proprietary cannabinoid healthcare app. The partnership aims to enhance instant analytics for multiple indications and critical ailments. CEO Simon Shainberg emphasizes the importance of this collaboration in gathering critical data and improving patient usage through AI integration.
The company has developed proprietary algorithms for healthcare professionals to analyze patient data and predict optimal cannabis products and dosages. Strainsforpains EBYH reported annual sales exceeding $300,000 in 2024 with just one product and plans to expand its offerings with AI medical intelligence. The company is also partnering with Cannabis Science to expand its patient outcome list and apply AI technology to critical ailment drugs and therapeutic medicines.
Strainsforpains (OTC: EBYH) has announced an alliance with the 1-Million Strong Killing Cancers, Fight Club (1MSFC) and plans for the Inaugural Live 1MSFC #1 MMA Fight in Q4 2024 in Florida. The company has appointed Steven A. Smith Jr., former WWE TV Executive VP, as COO of 1MSFC. The initiative aims to raise awareness and funds for Cannabis Science's low-cost cancer-killing drugs through quarterly live televised MMA events and other diverse activities. EBYH and Cannabis Science will promote these events to support the commercialization of Harvard Award-winning cancer treatments. The partnership seeks to leverage the growing MMA entertainment sector and influencer culture to drive global awareness for the '1-Million Strong Killing Cancers' movement.
Strainsforpains Inc. (OTC: EBYH) has signed a strategic product commercialization agreement with Cannabis Science Inc. for international retail and wholesale cannabinoid drug distribution. The partnership aims to leverage Cannabis Science's product pipeline, including its Harvard Award-winning cancer research and CBN patent for sleep and neurological disorders. CEO Simon Shainberg projects strong revenue growth for 2024, citing recent orders totaling $195,000 and partnerships with hemp farmers in Virginia and Pennsylvania. The company expects to surpass $500,000 in sales for 2024 and is expanding its CBD product line. The collaboration with Cannabis Science is expected to fuel rapid growth and potentially lead to a NASDAQ uplisting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.